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Abstract
The efficacy of imidacloprid 10 %/moxidectin 2.5 % 
(Advocate®, Advantage® Multi, Bayer) against 
experimental Dirofilaria (D.) repens infection in 
dogs was evaluated in a blinded, negative con-
trolled randomised laboratory efficacy study. On 
SD (study day) 0, eight dogs received a spot-on 
treatment at a dose of 10 mg imidacloprid and 
2.5 mg moxidectin per kg body weight. Another 
8 dogs were left untreated. On SD 28 each dog was 
infected with approximately 75 infective D. repens 
larvae. Blood samples were collected every 4 weeks 
after treatment. A modified Knott test was con-
ducted to detect mf (microfilaria). PCR analysis 
was performed with mf-positive blood samples. 
On SDs 245 and 246, all dogs were euthanised for 
detection of D. repens worms. Blood samples of all 
treated dogs were negative for mf at all sampling 
days. Blood samples of control dogs were positive 
for mf in 5 out of 8 control dogs. Individual mf 
counts ranged from 7 to 2800 mf/ml. In mf-positive 
blood samples, only D. repens was identified by 
PCR analysis. During necropsy D. repens worms 
could be detected in eight untreated control dogs 
(range: 3–21 worms per dog), whereas no worm 
could be detected in any of the treated dogs. These 
results indicate a 100 % preventive efficiency of a 
single spot-on treatment of imidacloprid 10 %/mox-
idectin 2.5 % in dogs against experimental infec-
tion with D. repens (L3 larvae). The product was 
well tolerated in all study animals, no treatment 





Dirofilaria repens (D. repens) Railliet and Henry, 
1911, is the main causative agent of subcutaneous 
filarial infections of dogs and cats in Europe and 
eastern countries (Svobodova et al. 2006; Fok 2007; 
Genchi et al. 2009; Miterpáková et al. 2010). Adult 
worms are localised mainly in subcutaneous con-
nective tissues and in perimuscular fasciae. Most 
infections are asymptomatic, however it has been 
reported that dogs with D. repens can present cuta-
neous disorders of varying severity, such as pru-
ritus, dermal swelling and subcutaneous nodules 
containing the adult or pre-adult parasites. Severe 
infections with allergic reactions likely due to 
microfilarial sensitisation have also been reported 
(reviewed by McCall et al. 2008; Genchi et al. 2011; 
Rocconi et al. 2012).
Adult female worms measure 13–17 cm in length 
and 460–650 µm in width, while the male worms 
are shorter (5–7 cm) (Anderson 1952) (Figs. 1 and 2). 
After mating, adult female worms release micro-
filariae (330–370 µm in length and 6–8 µm in 
width) into the blood stream of the host. Circulat-
ing microfilariae are taken up by bloodsucking 
female mosquitoes, mostly of the genera Anopheles, 
Culex and Aedes (Cancrini et al. 2007), and develop 
to the infective larval stage (L3), which are trans-
mitted to the final host through the subsequent 
blood meal of the infected mosquito (Fig. 3). The 
development of infective larvae in mosquitoes is a 
temperature-dependent process and at optimal 
temperature of 28 °C it takes about 30 days. The 
prepatent period lasts about 6.5–9 months, and 
patency from 5 to 7 years (Weber and Hawking 
1955; Anderson 2000). Dogs are the main reservoir, 
cats and wild carnivores such  as foxes being sel-
dom microfilaraemic (Magi et al. 2008).
In dogs, D. repens infection is currently diagnosed 
by Knott test for circulating microfilariae as, until 
Fig. 1  Adult male of Dirofilaria repens from the untreated 
control group. White square indicates area of Fig. 2
Fig. 2  Enlargement from Fig. 1 showing the typical  
longitudinal ridges on the cuticula
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now, no serological test kits for the detection of cir-
culating antibodies or antigens are available for 
veterinary practitioners. As a consequence, consid-
ering the few cases with clinical symptoms of sus-
picion, most cases run undiagnosed and infected 
dogs continue for long time to act as active reser-
voirs of infection, mainly throughout the movement 
and relocation of dogs from endemic areas of South 
and Southeast Europe to northern countries such 
as Germany, Poland and Hungary (Genchi et al. 
2009; Pantchev et al. 2009; Sassnau et al. 2009). 
Although subcutaneous dirofilariosis is consid-
ered of minor clinical concern in animals because 
the frequent lack of abnormalities, the parasite 
can cause benign to severe/very severe infections 
in humans. Overall, more than one thousand of 
human infections have been reported until now 
(Pampiglione and Rivasi 2000; Genchi et al. 2011; 
Simón et al. 2012). In most cases, D. repens is not 
able to develop to adult, sexually mature stage in 
human hosts, and infection is characterised by 
the presence of preadult stages located in subcu-
taneous tissues of different body areas, close to 
the original mosquito bite, although four cases of 
microfilaraemic zoonotic infections have been until 
now reported in Europe (Nozais et al. 1994; Petro-
cheilou et al. 1998; Supriaga et al. 2004; Kucsera 
2011, personal communication). Besides subcuta-
neous and ocular localisation, the parasite has been 
shown to infect viscera as well as female breast 
Fig. 3 Schematic representation of the life cycle of Dirofilaria repens 
5. The development 
from microfilaria to infective 
L3 happens inside the 
mosquito and takes 
approx. 10 – 30 days.
1. Infective L3 
are transmitted during 
a blood meal to the 
next host.
Dogs are the primary 
host of the skin worm 
Dirofilaria repens.
4. Mosquito 
takes up microfilaria 
from an infected dog.
3. Adult worms live in 
nodules under the skin and 
release microfilaria which 
circulate in the blood.
2. L3 move to the 
subcutaneous tissue and 




be infected as 
well and develop 
a similar disease: 
worms develop 
in subcutaneous 




and male genitalia (e.g. scrotum, penis, spermatic 
cord and epididymis). Furthermore, several pulmo-
nary localisations have been reported. Deep tissue 
localisation of the parasitic nodule usually leads to 
a clinical suspicion of neoplasia and requires biopsy 
or more invasive surgery for differential diagnosis 
through histology and morphologic identification 
of the parasite, thus causing emotional distress 
and costly intervention. In some cases, infections 
have been described as mimicking cervical intra-
dural Langerhans cell histiocytic tumors, or scrotal 
tumors, or as leading to severe consequences due 
to intraperitoneal localisation (reviewed by Genchi 
et al. 2011; Simón et al. 2012).
The only effective and safe measure to protect 
humans from the risk of infection is to control sub-
cutaneous dirofilariosis in dogs. Several macro-
cyclic lactones (ivermectin, milbemycin oxime, 
moxidectin and selamectin) have been shown to be 
fully efficacious to prevent heartworm (Dirofilaria 
immitis) infection both in dogs and cats throughout 
experimental and field studies (reviewed by McCall 
et al. 2008), but only few studies have been carried 
out against D. repens. Most studies have been con-
ducted as field studies. Oral ivermectin (Marconcini 
et al. 1993; Pollono et al. 1998), topical selamectin 
(Genchi et al. 2002a) and oral moxidectin (Rossi 
et al. 2002) have been reported to be effective to 
prevent D. repens-patent infections in dogs living 
in endemic areas when administered every 30 days 
during Dirofilaria transmission season, while one 
injection of moxidectin as a sustained release for-
mulation is able to protect from infection through-
out the entire transmission season (Rossi et al. 
2004). In most studies, the efficacy was assessed 
comparing the results with the infection prevalence 
observed in the previous year(s). 
In 1989, Cancrini et al. (1989) carried out a study 
in experimental infected dogs with ivermectin as a 
preventative. Dogs were infected 4 times, 15 days 
apart, with D. repens-infective larvae (estimated 
total challenge 484–919 infective larvae) and 
treated orally with ivermectin at dose rates of 
6 µg, 12 µg and 24 µg/kg body weight (b.w.) given 
30 and 60 days after the first infection. At necropsy 
8 months later, the efficacy was 86.6 %, 92.8 % and 
87.9 %, respectively. 
Recently, Genchi et al. (2010) have shown the full 
efficacy of moxidectin at the dose of 0.17 mg/kg 
b.w. in a microsphere sustained release injectable 
formulation when administered six months after 
experimental infection of dogs. 
The present study was carried out to assess the 
efficacy of an imidacloprid 10 % / moxidectin 2.5 % 
spot-on formulation (Advocate®, Advantage® Multi, 
Bayer) to prevent D. repens infection in experimen-
tally infected dogs.
Material and methods
The study was conducted as a randomised, place-
bo-controlled and blinded efficacy study designed 
and conducted in accordance with the standards 
of VICH GL7 (Efficacy of anthelmintics: general 
requirements, 11/2000), VICH GL9 (Good Clinical 
Practice, 06/2000) and VICH GL19 (Effectiveness 
of anthelmintics: specific recommendations for 
canine, 06/2000). Because the guidelines do not 
include any specific information on D. repens, the 
animal infection was carried out on the basis of pre-
vious experimental studies on the development of 
this filarial species in the dog (Webber and Hawk-
ing 1955; Genchi et al. 2010) and in accordance 
with the WAAVP guidelines for evaluating the 
efficacy of anthelmintics for dogs and cats (Jacobs 
et al. 1994). 
Efficacy criterion
The study was designed as an efficacy study. There-
fore the primary criterion for efficacy was the result 
of the necropsy D. repens counts. The primary vari-
able evaluated was the efficacy of the combination 
of imidacloprid 10 %/moxidectin 2.5 % against infec-
tive larvae of D. repens. The efficacy evaluation was 
assessed through the number of adult worms recov-
ered 8 months after dog infection (245–246 days). 
A statistically significant difference between the 
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mean value of the treatment group and the control 
group (p < 0.05) and 90 % geometric mean percent 
reduction relative to the untreated control group 
was required for efficacy of the treatment.
Further parameters were connected with the gen-
eral welfare of the dogs, their suitability for inclu-
sion in the study and the safety evaluation of the 
combination of imidacloprid 10 %/moxidectin 2.5 % 
(clinical assessments).
Study design
Sixteen Beagle dogs, 8 male (7.6–8.7 kg body weight 
(b.w.) and 8 female (6.3–7.4 kg b.w.) dogs, aged 5 to 
6 months at beginning of the study, were included 
in the study. After acclimatisation for 7 days, on 
study day –3 dogs were blocked by body weight and 
gender and randomly allocated to two study groups 
(8 dogs per group). Dogs were housed in groups 
of 2 animals of the same sex in pens according to 
the “Commission recommendation on guidelines 
for the accommodation and care of animals used 
for experimental and other scientific purposes” 
(2007/526/EC – 18/06/07). On study day –7, blood 
samples were taken from each dog and examined 
by Knott test for circulating microfilariae (Knott 
1939; Genchi et al. 2007). 
On study day 0, 8 dogs were treated with the com-
bination of imidacloprid 10 %/moxidectin 2.5% at a 
dose of 10 mg imidacloprid and 2.5 mg moxidectin 
per kg b.w. (group 1), while 8 dogs (placebo-treated, 
group 2) served as control. On study day 28, all 
dogs were experimentally infected with approxi-
mately 75 infective larvae of D. repens. Overall, 
the study lasted 245–246 days, when dogs were 
humanely euthanised for necropsy and pre-adult 
and adult worms were collected and counted. After 
treatment, blood samples were individually taken 
at study days 28, 56, 84, 112, 120, 140, 168, 196, 
224 and 238 and examined by Knott test. Micro-
filaraemic samples were examined by PCR, using 
primers for identification of different filarial spe-
cies, including D. repens as previously described 
by Gioia et al. (2010).
Throughout the study, the dogs were fed once per 
day with a commercial diet and drinking water was 
supplied at libitum. General health observations 
were carried out on all dogs daily from study day 
–7 to study day 0 (treatment day) and again at 1 
and 4 hours post treatment and daily until the end 
of the study. Dogs were weighted prior to feeding 
on study days –7 and –3 and again each 2–3 weeks 
throughout the entire study.
Preparation of D. repens-infec tive larvae 
and experimental infection
Infective larvae were obtained as previously 
described by Genchi et al. (2010). Briefly, approxi-
mately 1.500 female pupae of Aedes aegypti were 
allowed to emerge as adults into a carton and 
4-day-old mosquitoes were used for producing 
infective larvae. Heparinised blood was collected 
from a naturally D. repens-infected dog. Infected 
blood was maintained at 37 °C in a feeding appara-
tus and mosquitos were allowed to feed. D. repens-
infective larvae were collected from mosquitoes 
after 28 days and put into 16 tubes, each containing 
approximately 75 larvae in 1.5 ml of fresh RPMI-
1640 medium. On study day 28 of the study, each 
dog was injected subcutaneously with 75 larvae in 
accordance with the WAAVP Guidelines (Jacobs 
et al. 1994 and Vercruysse et al. 2002). 
Statistical analysis
The efficacy was assessed based on the number of 
D. repens worms found at necropsy in the treated 
dog group compared to the untreated dog group. 
Efficacy was calculated based on geometric means 
(GM). Percent efficacy was calculated as [(GM 
control – GM treated)/GM control] x 100. The sta-
tistical analysis was carried out with the non-para-
metric Wilcoxon-Mann-Whitney-U Test (two-sided, 
alpha = 0.05) for the group comparisons. The medi-
cal relevance of the differences between groups 
was quantified using the Mann-Whitney superi-
ority measure (MW) and its two-sided 95.0 % con-
fidence interval as corresponding effect size. The 
MW measure (0.0 to 1.0) reflects the probability 
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that a randomly selected patient of the test group 
is better off than a randomly selected patient of the 
control group (Coldiz et al. 1988).
Results
Dogs in group 1, treated with the combination of 
imidacloprid 10 %/moxidectin 2.5 %, were negative 
at all Knott test examinations carried out at the 
different times of the study. In group 2 (placebo-
treated) no D. repens microfilariae were found in 
3 dogs at any study time. On study day 196, 3 dogs 
were microfilaraemic. The individual number of 
microfilariae per ml was 10, 22 and 229. On study 
day 224, 5 dogs were microfilaraemic; the indi-
vidual number of microfilariae/ml was 174, 105, 
1,410, 370 and 7. On study day 238, the same dogs 
were still positive with an individual number of 
microfilariae per ml of 510, 870, 2,800, 700 and 30, 
respectively (Table 1) showing a time-dependent 
increase of microfilaria counts. PCR analysis on the 
microfilaraemic blood samples confirmed that the 
infection was caused by D. repens.
At necropsy, all dogs were examined for preadult 
and adult D. repens worms. All placebo treated 
dogs were found to be infected with worms (range: 
3 to 21 worms). Data counts are shown in Table 2. 
Seven out of 8 dogs had 5 or more adult worms 
in subcutaneous tissues. At necropsy on study 
day 245 and 246, no worm was found in any of 
the imidacloprid 10 %/moxidectin 2.5 %-treated 
dogs (group 1, efficacy 100 %). The imidacloprid 
10 %/moxidectin 2.5 %-treated group was highly 
Table 1  Number of Dirofilaria repens microfilariae/ml in placebo-treated dogs from study day 196 to study day 238  
after experimental infection
Dog ID Study day 196 Study day 224 Study day 238
9478 0 0 0
8544 10 174 510
9800 22 105 870
8838 139 1410 2800
9583 0 370 700
9257 0 0 0
9176 0 7 30
9893 0 0 0
Table 2  Number of Dirofilaria repens worms found in the placebo-treated dogs on study day 245/246  
after experimental infection







countsDog ID live dead live dead
9478 2 0 1 0 0 3 0 3
8544 2 0 2 0 1 4 1 5
9800 3 0 3 0 2 6 2 8
8838 7 4 8 1 1 15 6 21
9583 4 1 4 0 1 8 2 10
9257 2 0 3 0 1 5 1 6
9176 7 0 8 0 2 15 2 17
9893 3 0 7 0 2 10 2 12
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statistical significant superior versus the untreat-
ed control group (p = 0.0002, MW = 1.0).
Throughout the study, no adverse reactions were 
observed in any of the dogs.
Discussion
Moxidectin has shown a potent prophylactic activ-
ity in preventing heartworm (D. immitis) infections 
when administered either at 1 or 2 months post 
infection in experimentally infected dogs (McTier 
et al. 1992). Effective prophylaxis has also been 
shown in dogs naturally exposed to heartworm-
infected mosquitoes treated orally either monthly 
at 1 µg/kg and 3 µg/kg b.w. or bimonthly at 3 µg/
kg b.w. (McCall et al. 1992). The sustained release 
injectable formulation (0.17 mg/kg b.w.) has been 
shown to be effective for at least 6 months both in 
field studies (Genchi et al. 2002b) and after experi-
mental heartworm infections (Lok et al. 2005). 
Moxidectin is more lipophilic in nature than iver-
mectin and it is stored in the fat, which may act as 
a drug reservoir (Vanapalli et al. 2002). Compared 
to ivermectin, moxidectin has a higher distribution 
volume and a longer half-life elimination (Vanapal-
li et al. 2002). This may facilitate its distribution 
from the bloodstream to different tissues and lon-
ger residence time for the drug in the body (Alvin-
erie et al. 1995; Vanapalli et al. 2002). D. repens 
larval stages and the adult worms are permanent 
residents in subcutaneous tissues, which are rich 
of connective and fat tissues. Therefore, the high 
lipophilic nature of moxidectin is probably the 
reason of the full efficacy observed in this study, 
treating experimentally infected dogs topically 
with a combination of imidacloprid 10 %/moxidectin 
2.5 %, confirming the previous data observed with 
an injectable formulation (Genchi et al. 2010). The 
efficacy was assessed in comparison with placebo-
treated dogs. Only 5 of 8 control dogs had a patent 
infection with an increasing number of circulat-
ing microfilariae during the course of infection, 
whereas all control dogs were infected with living 
worms. Advocate® was well tolerated in all treat-
ed animals as no side effects were observed. The 
lack of clinical alterations after the experimental 
infection confirms that most D. repens infections 
are clinically undetectable. In conclusion, imidaclo-
prid 10 %/moxidectin 2.5 % (Advocate®, Advantage® 
Multi, Bayer) can be considered an effective and 
safe preventative product against D. repens infec-
tions in dogs.
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